ArticleIranian journal of basic medical sciences2026
Neuroprotective effects of ROCK inhibition on hippocampal energy metabolism in a rat model of metabolic syndrome.
Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Metabolic syndrome (MS) is associated with insulin resistance, hyperglycemia, and dyslipidemia, leading to impaired neuronal energy metabolism and hippocampal dysfunction. Rho-associated kinase (ROCK) has been implicated in metabolic and neuroinflammatory dysregulation; however, its role in MS-induced hippocampal energy imbalance remains unclear. This study aimed to determine whether pharmacological ROCK inhibition with fasudil restores hippocampal energy metabolism in a rat model of fructose-induced MS. Materials and Methods: Male Lewis rats were divided into control, MS, and MS+fasudil groups. Plasma and hippocampal metabolic parameters were assessed using biochemical assays. Activities of glycolytic enzymes, Krebs cycle enzymes, and mitochondrial respiratory chain complexes I--IV were measured. Phosphatidylinositol 3-kinase/Protein kinase B/Mechanistic target of rapamycin (PI3K/AKT/mTOR) pathway components, including phosphorylated PI3K, AKT, mTOR, Phosphatase and tensin homolog (PTEN), and Ras homolog enriched in brain (Rheb), were analyzed by Western blotting. Results: MS disrupted glucose homeostasis and significantly suppressed the activities of glycolytic, mitochondrial, and respiratory chain enzymes in the hippocampus. These changes were accompanied by reduced phosphorylation of PI3K, AKT, and mTOR, increased PTEN expression, and decreased Rheb levels, indicating impaired PI3K/AKT/mTOR signaling. Fasudil treatment normalized plasma and hippocampal glucose levels, restored enzymatic activities across major energy-producing pathways, and reactivated PI3K/AKT/mTOR signaling by reducing PTEN and restoring AKT and Rheb activity. Conclusion: These findings demonstrate that ROCK overactivation contributes to central insulin resistance and hippocampal energy dysfunction in MS. ROCK inhibition with fasudil effectively reverses these alterations, highlighting ROCK as a potential therapeutic target for preserving hippocampal metabolic function in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.